Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors

Journal of Medicinal Chemistry

Volumn 39, Issue 20, 1996, Pages 4017-4026

  Dukat, Malgorzata ^a   Abdel Rahman, Ashraf A ^a   Ismaiel, Abd M ^a   Ingher, Stacy ^b   Teitler, Milt ^b   Gyermek, Laszlo ^c   Glennon, Richard A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 METHYL 1H IMIDAZOL 4 YL) 1 (1 METHYL 1H INDOL 3 YL) 1 PROPANONE; BEMESETRON; BIGUANIDE DERIVATIVE; GUANIDINE DERIVATIVE; PHENYLBIGUANIDE; PIPERAZINE DERIVATIVE; QUIPAZINE; SEROTONIN 3 AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; TROPISETRON;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLADDER CONTRACTION; BRADYCARDIA; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; INTRAARTERIAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIGAND BINDING; MALE; NONHUMAN; RABBIT; RAT; RECEPTOR AFFINITY; REFLEX; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIGUANIDES; HEART RATE; MALE; MOLECULAR STRUCTURE; MUSCLE CONTRACTION; PIPERAZINES; RABBITS; RATS; RECEPTORS, SEROTONIN; REFLEX; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; URINARY BLADDER;

EID: 0029822173     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9603936     Document Type: Article

References (67)

1. 3 receptors. Med. Res. Rev. 1990, 10, 441-475.
2. 3 receptors. Pharmacol. Ther. 1990, 47, 181-202.
3. Zifa, E.; Fillion, G. 5-Hydroxytryptamine receptors. Pharmacol. Rev. 1992, 44, 401-458.
4. Glennon, R. A.; Dukat, M. 5-HT Receptor ligands - Update 1992. Curr. Drugs: Serotonin 1992, 1-45.
5. King, F. D., Jones, B. J., Sanger, G. J., Eds. 5-Hydroxytryptamine-3 Receptor Antagonists; CRC Press: Boca Raton, FL, 1994.
6. 3 receptors: Pharmacologic and therapeutic aspects. J. Clin. Pharmacol. 1995, 35, 845-855.
7. Fozard, J. R. MDL 72222; a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 1984, 326, 36-44.
8. 3 serotonin receptors. Med. Chem. Res. 1991, 1, 271-276.
9. 3 agonists and antagonists. Rev. Neurosci. 1988, 2, 41-65.
10. 3 receptors. In Neuronal Serotonin; Osborne, N. N., Hamon, M.. Eds.; John Wiley and Sons: New York, 1988; pp 465-506.
11. Glennon, R. A.; Dukat, M. Serotonin receptors and their ligands. A lack of selective agents. Pharmacol. Biochem. Behav. 1991, 40, 1009-1017.
12. 3 receptor agonist. Eur. J. Pharmacol 1990, 182, 193-197.
13. 3 receptor ligands and substance P. J. Neurochem. 1993, 60, 2059-2067.
14. Round, A.; Wallis, D. I. Further studies on the blockade of 5-HT depolarizations of rabbit vagal afferent and sympathetic ganglion cells by MDL 72222 and other antagonists. Neuropharmacology 1987, 26, 39-48.
15. Ireland, S. J.; Tyers, M. B. Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the isolated vagus nerve. Br. J. Pharmacol. 1987, 90, 229-238.
16. 3 receptor antagonists based on the arylpiperazine skeleton: Synthesis, structure, biological activity, and comparative molecular field analysis studies. J. Med. Chem. 1995, 38, 2692-2704.
17. 3 serotonin receptors: Results of a structure-affinity study. Eur. J. Pharmacol. 1989, 168, 387-392.
18. 3 recognition sites in rat cortical membranes. Eur. J. Pharmacol. 1988, 148, 297-299.
19. 13H]Quipazine degradation products label 5-HT uptake sites. Eur. J. Pharmacol. 1989, 171, 141-143.
20. 3 serotonin receptors. Abstracts, 2nd International Symposium on Serotonin, From Cell Biology to Pharmacology and Therapeutics, Houston, TX, Sept 15-18, 1992; p 42.
21. Morain, P.; Abraham, C.; Portevin, B.; DeNanteuil, G. Biguanide derivatives: Agonist pharmacology at 5-hydroxytryptamine Type 3 receptors in vitro. Mol. Pharmacol. 1994, 46, 732-742.
22. Bysouth, P. T.; Clarke, R. W. S. African Patent 6804, 082, 1969; Chem. Abstr. 1969, 71, 91527.
23. Bysouth, P. T.; Clarke, R. W. S. African Patent 6804, 082, 1969; Chem. Abstr. 1969, 71, 91527.
24. McKenney, J. D. Ph.D. Dissertation, MCV/Virginia Commonwealth University, Richmond, VA, 1984.
25. Brewster, K.; Coult, D. B.; Pinder, R. M. 1-Phenylpiperazines: potential antagonists of lysergic acid diethylamide. Chim. Ther. 1972, 2, 87-91.
26. Newkome, G. R.; Roper, J. M. Polyorganometalic heterocycles, 2,6-dilithiopyridine. J. Organomet. Chem. 1980, 186, 147-153.
27. Sheean, J. C.; Bolhofer, W. A. An improved procedure for the condensation of potassium phthalimide with organic halides. J. Am. Chem. Soc. 1950, 72, 2786-2788.
28. Farbwerke Hoechst, A.-G. 3-Phenylpropylamides of isonicotinic acid. Chem. Abstr. 1968, 68, 78141v.
29. Short, J. H.; Darby, T. D. Sympathetic nervous system blocking agents. III. Derivatives of benzylguanidine. J. Med. Chem. 1967, 10, 833-840.
30. 3 antagonists on spontaneous and induced electrocortical activity in the rat. Eur. J. Pharmacol. 1990, 183, 1969.
31. Rizzi, J. P.; Nagel, A. A.; Rosen, T.; McLean, S.; Seeger, T. An initial three-compartment pharmacophore for specific serotonin-3 receptor ligands. J. Med. Chem. 1990, 33, 2721-2725.
32. 3 receptor antagonist activity. In 5-Hydroxytryptamine-3 Receptor Antagonists; King, F. D., Jones, B. J., Sanger, G. J., Eds.; CRC Press: Boca Raton, FL, 1994; pp 67-78.
33. Gyermek, L. Action of guanidine derivatives on autonomic ganglia. Arch. Int. Pharmacodyn. Ther. 1964, 150, 570-581.
34. Shapiro, S. L.; Parrino, V. A.; Rogow, E.; Freedman, L. Hypoglycemic agents. Arylbiguanides. J. Am. Chem. Soc. 1959, 81, 3725-3736.
35. Ernst, S. R.; Cagle, F. W. Biguanide. Acta Crystallogr. 1977, B33, 235-237.
36. 6·HCl. Bull. Soc. Chim. Belg. 1985, 94, 119-121.
37. Brown, C. J. The crystal structure of 1-(p-chlorophenyl)-5-isopropylbiguanide hydrochloride ("Paludrine"). J. Chem. Soc. A 1967, 60-65.
38. Fastier, F. N. Structure-activity relationships of amidine derivatives. Pharmacol. Rev. 1962, 14, 37-90.
39. 3 receptor antagonists. J. Med. Chem. 1990, 33, 2715-2720.
40. 2 binding characteristics of some quipazine analogues. J. Med. Chem. 1986, 29, 2375-2380.
41. Lyon, R. A.; Titeler, M.; McKenney, J. D.; Magee, P. S.; Glennon, R. A. Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J. Med. Chem. 1986, 29, 630-634.
42. 3 serotonin receptors: Results of a structure-affinity study. Eur. J. Pharmacol. 1989, 168, 387-392.
43. Lumma, W.; Saari, W. U.S. Patent 4,078,063, 1978.
44. Lugaro, G.; Torti, G.; Giannattasio, G.; Perani, G. Antitumor activity of biguanides. Arch. Ital. Patal. Clin. Tumori 1967, 10, 211-222; Chem. Abstr. 1968, 69, 51761f.
45. Lugaro, G.; Torti, G.; Giannattasio, G.; Perani, G. Antitumor activity of biguanides. Arch. Ital. Patal. Clin. Tumori 1967, 10, 211-222; Chem. Abstr. 1968, 69, 51761f.
46. Curd, F. H. S.; Rose, F. L. Synthetic Antimalarials. Part IV. 2-Phenylguanidino-4-aminoalkylammo-6-methylpyrimidines. J. Chem. Soc. 1946, 362-366.
47. Shapiro, S. L.; Parrino, V. A.; Rogaw, E.; Freedman, L. Arylbiguanides. J. Am. Chem. Soc. 1959, 81, 3725-3728.
48. Slopek, S.; Mordarska, H.; Mordarski, M.; Urbanski, B.; Skowronska-Serafin, B.; Dabrowska, H. Antineoplastic activity of some guanidine derivatives. Chem. Abstr. 1958, 52, 20605a.
49. Wright, W. B.; Barbander, H. J.; Hardy, R. A.; Osterberg, A. C. Central nervous system depressants. I. 1-Aminoalkyl-3-aryl derivatives of 2-imidazolidinone,la-c 2-imidazolidinethione, and tetrahydro-2(1H)-pyrimidinone. J. Med. Chem. 1966, 9, 852-857.
50. Fuller, R. W.; Roush, B. W.; Snoddy, H. D.; Day, W. A.; Molloy, B. B. Norepinephrine N-methyl transferase inhibition by benzamidines, phenylacetamidines, benzylguanidines, and phenylethylguanidines. J. Med. Chem. 1975, 18, 304-307.
51. King, H.; Tonkin, I. M. Antiplasmodial action and chemical constitution. Part VIII. Guanidines and diguanides. J. Chem. Soc. 1946, 1063-1069.
52. Hughes, J. L.; Chung-Huan, R. L.; Enkoji, T.; Bastian, J. W. Pharmaceutical guanidine preparations and methods of using. U.S. Patent 3, 976, 787, 1976.
53. Hughes, J. L.; Liu, R. C.; Enkoji, T.; Smith, C. M.; Bastian, J. W.; Luna, P. D. Cardiovascular activity of aromatic guanidine compounds. J. Med. Chem. 1975, 18, 1077-1088.
54. Heesing, A.; Schmaldt, W. The substituent effect of the guanidino and of the guanidinium group. Chem. Ber. 1978, 111, 320-334.
55. Bruan, C. E. The preparation of some structurally related monoguanidines. J. Am. Chem. Soc. 1933, 55, 1280-1284.
56. Hughes, J. L.; Chung-Huan, R. L. Pharmaceutical aromatic guanidine compositions and methods of using. U.S. Patent 3, 908, 013, 1975.
57. Doht, R. Study of chlorophenylureas. Monatsh. Chem. 1906, 27, 213-223.
58. Pal, B.; Laszlo, P.; Ferene, O.; Rosdy, B. Formamidines. Hungarian Patent 156, 474, 1969.
59. Shapiro, S. L.; Isaacs, E. S.; Bandurco, V.; Freedman, L. Apparent dissociation constants of haloaralkyl- amines. J. Med. Pharm. Chem. 1962, 5, 793-799.
60. Mills, J.; Lilly, E. Aryl acetamidines. U.S. Patent 3, 445, 517, 1969.
61. Cavallini, G.; Milla, E.; Grumelli, E.; Massarani, E.; Nardi, D. Substituted 2-benzylimidazoline derivatives of pharmacological activity. Farmaco Ed. Sci. 1956, 11, 633-661.
62. Portnyagina, V. A.; Danilenko, V. F.; Denisov, N. D.; Vinnikova, A. V. Guanidine derivatives of nitrogen heterocycles. Chem. Heterocycl. Compd. 1971, 7, 230-231.
63. Boyer, R. Some guanidine and diguanide derivatives. J. Chem. Soc. 1949, 1665-1666.
64. Konig, H.; Huisgen, R. Further ring-closure reactions via arynes. Chem. Ber. 1959, 92, 429-441; Chem. Abstr. 1959, 11401e.
65. Konig, H.; Huisgen, R. Further ring-closure reactions via arynes. Chem. Ber. 1959, 92, 429-441; Chem. Abstr. 1959, 11401e.
66. 3 recognition sites by radioligand binding in NG 108-15 neuroblastoma glioma cells. Eur. J. Pharmacol. 1987, 143, 291-292.
67. Gyermek, L. Methods for the examination of ganglionic blocking activity. Handbk. Exp. Pharmacol. 1980, 53, 63-121.